Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Common Equity (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Common Equity for 16 consecutive years, with $5.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 197.68% to $5.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.1 million, a 197.68% increase, with the full-year FY2024 number at -$8.9 million, down 563.87% from a year prior.
  • Common Equity was $5.1 million for Q3 2025 at Plus Therapeutics, up from $3.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $14.8 million in Q3 2021 to a low of -$23.6 million in Q1 2025.
  • A 5-year average of $2.4 million and a median of $2.9 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 11091.76% in 2021, then crashed 563.87% in 2024.
  • Plus Therapeutics' Common Equity stood at $14.8 million in 2021, then tumbled by 56.32% to $6.4 million in 2022, then crashed by 120.92% to -$1.3 million in 2023, then plummeted by 563.87% to -$8.9 million in 2024, then soared by 156.48% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Common Equity are $5.1 million (Q3 2025), $3.0 million (Q2 2025), and -$23.6 million (Q1 2025).